New study shows promising results for male contraceptive pills


PTI, Jun 12, 2022, 9:19 AM IST

According to a new study, two experimental male contraceptive tablets appear to efficiently suppress testosterone without generating undesirable side effects. The findings will be presented at the annual conference of the Endocrine Society in Atlanta, Georgia.

The drugs, called DMAU and 11b-MNTDC, are part of a class of drugs called progestogenic androgens. These drugs suppress testosterone, which lowers sperm count. Lowering testosterone levels normally leads to unpleasant side effects, but most of the men in the study were willing to continue using the drugs, suggesting the side effects were acceptable.

“Male contraception options are currently restricted to vasectomy and condoms, and are thus extremely limited as compared to female options,” said lead researcher Tamar Jacobsohn of the Contraceptive Development Program at the Eunice Kennedy Shriver National Institute of Child Health and Human Development. “Development of an effective, reversible male contraceptive method will improve reproductive options for men and women, have a major impact on public health by decreasing unintended pregnancy, and allow men to have an increasingly active role in family planning.”

 

The study included 96 healthy male participants in two Phase 1 clinical trials. In each trial, the men were randomly assigned to receive two or four oral pills of active drug or placebo daily for 28 days. After seven days on the active drug, testosterone levels dropped below normal range. In men taking the placebo, testosterone levels stayed within the normal range. The study found 75 per cent of men who took the active drug said they would be willing to use it in the future, compared with 46.4 per cent of those taking a placebo. Men who took the four-pill daily dose (400 milligrams) had lower levels of testosterone than those taking the two-pill, 200-milligram dose. There was no significant difference between the two active treatment groups in satisfaction with the drug, or willingness to use it in the future or recommend it to others.

“Men’s positive experiences in clinical trials and high ratings of acceptability for this male pill should serve to excite the public about male birth control being potentially widely available in the coming decades,” Jacobsohn said.

(With inputs from ANI)

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

Actress Kasthuri released from jail, says ‘I thank those who made me raging storm’

Kidnapped for ransom in 1998, 26/11 survivor Gautam Adani faces biggest trial

100 engineering colleges in Karnataka to be ‘adopted’ by corporates by next year: IT Minister Kharge

Siddaramaiah defends BPL ration card cancellation, says only ineligible beneficiaries affected

China announces new policy measures to protect its exports from Trump’s new tariff threat

Renovated Medical Oncology OPD and Chemotherapy Day Care Centre inaugurated at Kasturba Hospital, Manipal

Karnataka Health Minister justifies revision of user fees in state-run hospitals

Related Articles More

World COPD Day: Know your lung function

As Delhi chokes with dangerous pollution levels, doctors warn of health risks for all

World Diabetes Day 2024: Kasturba Hospital Manipal Hosts Zumba Session at Malpe Beach to Raise Diabetes Awareness

World Diabetes Day: An overview of types of diabetes

World Diabetes Day: One-fourth of people living with diabetes in 2022 are in India, Lancet study estimates

MUST WATCH

Christmas Cake Fruit Mixing

DK Shivakumar

Rose Cultivation

Geethotsava

Naxal Operation


Latest Additions

Siddaramaiah says confident of winning all three bypolls in Karnataka

Hop on! IT Minister Priyank Kharge checks out Uber Shuttle at Bengaluru Tech Summit

Actress Kasthuri released from jail, says ‘I thank those who made me raging storm’

Kidnapped for ransom in 1998, 26/11 survivor Gautam Adani faces biggest trial

AIMPLB to hold its annual general sessions in Bengaluru from November 23

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.